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On the basis of our earlier studies with serotonin receptor ligands in the group of long-chain arylpiperazine derivati-
ves of purine-2,6-dione, a series of new 7-arylpiperazinylbutyl-8-morpholinyl-purine-2,6-dione analogs (GR-26/10, 
GR-27/10, GR-28/10) was designed, synthesized and studied in in vitro assays for the affi nity of these compounds 
for 5-HT1A, 5-HT2A and 5-HT7 receptors. We have shown that the introduction of a methoxy moiety at the 2-position or 
a chloride atom at the 3-position of the phenylpiperazine structure of 8-morpholin-4-yl-purin-2,6-dione modifi ed the 
affi nity for 5-HT1A, 5-HT2A and 5-HT7 receptors as compared with the unsubstituted parent compound (GR-26/10). 
Then the selected compounds were pharmacologically evaluated in mouse models of depression and anxiety, i.e. the 
forced swim and the four-plate tests, respectively. Among them, the GR-28/10 compound with a chloride substi-
tuent at the 3-position of phenylpiperazine revealed specifi c anxiolytic, but not antidepressant, activity in mice. 
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INTRODUCTION
The serotonin (5-hydroxytryptamine, 5-HT) neu-
rotransmitter system regulates complex sensory, 
motor, affective, and cognitive functions. During 
the past several years a large amount of informa-
tion about 5-HT receptors has been collected, but 
the role of some of them is still unclear. The spe-
cifi c localization of 5-HT receptors in the central 
nervous system as well as high affi nity of some 
antidepressant and/or antipsychotic drugs for 
these receptors may suggest their involvement in 
32 Jastrzębska-Więsek et al.
affective disorders (CARR and LUCKI, 2011; HIRANO 
et al., 2009; MATTSON et al., 2005). Among 5-HT 
receptors, particularly the 5-HT1A, 5-HT2A, 5-HT6 
and/or 5-HT7 types are associated with anxiety, 
depression, and schizophrenic symptoms, and 
learning and memory disorders (CARR and LUCKI, 
2011; WESOŁOWSKA, 2010; WESOŁOWSKA and NIKI-
FORUK, 2008; WESOŁOWSKA, 2007; WESOŁOWSKA et 
al., 2007; WESOŁOWSKA et al., 2006). Postsynaptic 
5-HT1A receptors are essential for producing an-
tidepressant- and/or anxiolytic-like effects of 5-
HT1A receptor agonists and possibly selective 5-HT 
reuptake inhibitors. 5-HT2A receptor antagonists 
may also produce potential antidepressant/an-
tipsychotic activity. Furthermore, studies have 
shown that by reducing the function of 5-HT7 re-
ceptors, antidepressant-like behavioral effects can 
be evoked (CARR and LUCKI, 2011).
Arylpiperazine is a core fragment of many bioac-
tive compounds exhibiting a variety of pharmaco-
logical effects. Previously, it has been shown that 
their pharmacological activity can be mediated by 
different subpopulations of 5-HT, dopamine and 
adrenergic receptors (LOPEZ-RODRIGUEZ et al., 2002; 
JURCZYK et al., 2004). The most thoroughly stu-
died group of arylpiperazine derivatives is the one 
called long-chain arylpiperazines (LCAPs) which 
have been recognized as 5-HT ligands, particu-
larly 5-HT1A, 5-HT2A and 5-HT7 ligands (JURCZYK et 
al., 2004; CHŁOŃ-RZEPA et al., 2007). Their general 
chemical structure contains an alkyl chain (two 
to four methylene units) attached to the N4 atom 
of the piperazine moiety and a terminal amide or 
an imide fragment. Some of our previous structu-
re-affi nity and structure-intrinsic activity studies 
were concerned with chemical modifi cations in 
a group of compounds containing a theophylli-
ne fragment and an arylpiperazine moiety. These 
compounds, in functional in vivo models, behaved 
like postsynaptic 5-HT1A antagonists (CHŁOŃ-RZEPA 
et al., 2007). To continue our research with the 
class of LCAP derivatives of theophylline, we de-
signed a novel series of 7-arylpiperazinylbutyl-8-
morpholinyl-purine-2,6-dione analogs (GR-26/10, 
GR-27/10, GR-28/10). The synthesis of these 
compounds was presented earlier (CHŁOŃ-RZEPA et 
al., 2010). Their structures were confi rmed by 1H 
NMR spectra and an elementary analysis. All the 
new compounds were tested for their affi nity for 
5-HT1A, 5-HT2A, and 5-HT7 receptors. On the basis 
of binding studies, the compounds GR-27/10 and 
GR-28/10 as hydrochloride salts were evaluated 
in preclinical models of anxiety and depression in 
mice.
MATERIAL AND METHODS
Drugs
The investigated compounds GR-26/10 (1,3-di
-methyl-8-morpholin-4-yl-7-[4-(4-phenyl-pi-
perazin-1-yl)-butyl]-3,7-dihydro-purine-2,6-dio-
ne hydrochloride), GR-27/10 (7-{4-[4-(2-metho-
xy-phenyl)-piperazin-1-yl]-butyl}-1,3-dimethyl-
8-morpholin-4-yl-3,7-dihydro-purine-2,6-dione 
hydrochloride), GR-28/10 (7-{4-[4-(3-chloro-phe-
nyl)-piperazin-1-yl]-butyl}-1,3-dimethyl-8-mor-
pholin-4-yl-3,7-dihydro-purine-2,6-dione hydro-
chloride) were synthesized at the Department of 
Pharmaceutical Chemistry, Jagiellonian University, 
Medical College in Cracow (CHŁOŃ-RZEPA et al., 2010). 
Diazepam (Polfa), imipramine hydrochloride (Pol-
fa), Tween 80 (Tween 80, Sigma Aldrich). The fol-
lowing radioligands were used: [3H]-5-CT (34.5 
Ci/mmol, NEN Chemicals), [3H]-8-OH-DPAT (170 
Ci/mmol, NEN Chemicals) and [3H]-ketanserin.
In in vivo experiments, all the compounds were 
administered intraperitoneally (i.p.) at a volume 
of 10 ml/kg body weight 60 (diazepam) or 30 
min (the remaining compounds) before the test. 
Imipramine hydrochloride was dissolved in di-
stilled water, whereas diazepam, GR-27/10, and 
GR-28/10 were suspended in 1% aqueous solu-
tion of Tween 80 immediately before administra-
tion.
Animals
The experiments were performed on male Albino 
Swiss mice (22-26 g) and were approved by the 
Local Ethics Commission for Animal Experiments 
of Jagiellonian University in Cracow. The animals 
were kept in groups of 12-20 mice in type III-1290 
cages (26.5 x 42.0 x 15.0 cm) at a room tempera-
ture of 22 ± 2ºC, under 12/12 h light/dark cycle, 
and had free access to food and water before the 
experiments. Each experimental group consisted 
of 6-9 animals/dose, and all the animals were 
used only once. The experiments were performed 
between 8 a.m. and 3 p.m.
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Statistical analysis
All the data are presented as the mean ± S.E.M. 
The statistical signifi cance of drug effects was eva-
luated using a separate analysis of variance (ANO-
VA), followed by Bonferroni’s post-hoc test; p<0.05 
was considered statistically signifi cant.
In vitro radioligand binding assays
All the assays were carried out on rat brain tis-
sues; inhibition constants (Ki) were determined 
from at least three separate experiments in which 
8-10 drug concentrations, run in triplicate, were 
used. The binding effect was terminated by rapid 
fi ltration through Whatman GF/B fi lters, followed 
by three 4 mL washes with the ice-cold incuba-
tion buffer. The radioligand concentration used 
in competition assays was equal to the Kd values 
obtained in the respective saturation experiment, 
that is 1, 0.6, and 0.5 nM for [3H]-8-OH-DPAT, 
[3H]-ketanserin and [3H]-5-CT, respectively.
The radioligand retained on the fi lters was 
measured by liquid scintillation counting (Be-
ckman LS 6500 apparatus) in 4mL scintillation 
FLUID (Akwascynt, BioCare). Binding isotherms 
of the tested compounds were analyzed by nonli-
near regression (Prism, GraphPad Software Inc., 
San Diego, USA), using the Cheng-Pursoff equa-
tion to calculate Ki values.
Serotonin 5-HT1A and 5-HT2A binding assays
Radioligand studies with native 5-HT1A and 5-HT2A 
receptors were conducted according to the metho-
ds described previously (JURCZYK at al., 2004). 
Briefl y, the following were used: for 5-HT1A assays, 
rat hippocampal membranes, [3H]-8-OH-DPAT 
(170 Ci/mmol, NEN Chemicals), and 5-HT (10 μM) 
for non-specifi c binding; for 5-HT2A assays [
3H]-
ketanserin (88.0 Ci/mmol, NEN Chemicals) and 
metysergide (1 μM) for non-specifi c binding.
Serotonin 5-HT7 binding assays
The 5-HT7 receptor binding assay was performed 
using rat hypothalamic membranes, according 
to the method described by Aguirre et al. (1998) 
with a minor modifi cation described previously 
(CHŁOŃ-RZEPA et al., 2007). In brief, the membrane 
aliquots were incubated in the presence of 3 μM
(±)-pindolol (to eliminate the binding to 5-HT1A 
and 5-HT1B receptors) with 0.5 nM [
3H]-5-CT (34.5 
Ci/mmol, NEN Chemicals) and 10 μM of 5-HT for 
non-specifi c binding.
In vivo experiments
Forced swim test in mice
The experiment was carried out according to the 
method of PORSOLT et al. (1978). Mice were indivi-
dually placed in a glass cylinder (25 cm high; 10 
cm in diameter) containing 6 cm of water main-
tained at 23-25°C, and were left there for 6 min. 
A mouse was regarded as immobile when it re-
mained fl oating on the water, making only small 
movements to keep its head above it. The total du-
ration of immobility was recorded during the last 
4 min of the 6-min test session.
Four-plate test in mice
The four-plate apparatus (BIOSEB) consists of a 
cage (25 x 18 x 16 cm) fl oored with four identi-
cal rectangular metal plates (8 x 11 cm) separa-
ted from one another by a gap of 4 mm. The top 
of the cage is covered with a transparent Perspex 
lid that prevents escape behaviour. The plates are 
connected to a device that can generate electric 
shocks. Following a 15-s habituation period, the 
animal’s motivation to explore a novel environ-
ment is suppressed by an electric foot shock (0.8 
mA, 0.5 s) every time it moves from one plate to 
another during a 1-min test session. This action 
is referred to as a ‘punished crossing’, and is fol-
lowed by a 3- s shock interval, during which the 
animal can move across plates without receiving 
a shock. 
Spontaneous locomotor activity in mice
The locomotor activity was recorded with an Opto 
M3 multi-channel activity monitor (MultiDevice 
Software v.1.3, Columbus Instruments). The mice 
were individually placed in plastic cages (22 x 12 x 
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13 cm) for a 30-min habituation period, and then 
the crossings of each channel (ambulation) were 
counted during the fi rst 1-min (i.e. the time equal 
to the observation period in the four-plate test) 
and 5-min experimental sessions. The cages were 
cleaned up with 70% ethanol after each mouse.
RESULTS AND DISCUSSION
It is well known that central 5-HT receptors play 
an essential role in a number of psychiatric disor-
ders such as anxiety, depression and schizophre-
nia. Apart from the well-established role of 5-HT1A 
and 5-HT2A receptors, the most recently identifi ed 
5-HT7 receptors are also implicated in the control 
of mood diseases. It has been recently reported 
that differently substituted arylpiperazine moie-
ties are often incorporated into the structure of 
5-HT7 receptor ligands (RAUBO et al., 2006). Hen-
ce, all purine-2,6-diones were evaluated for their 
in vitro affi nity, not only for 5-HT1A and 5-HT2A 
receptors, but also for 5-HT7 sites. The newly 
synthesized derivatives of 7-arylpiperazinylbutyl-
8-morpholinyl-purine-2,6-dione analogs showed 
a diversifi ed level of affi nity for the investigated 
5-HT receptors, with Ki values ranging from 7 to 
1277 nM. The receptor binding data of new com-
pounds are presented in Table 1. Generally, in 
comparison with the previously reported butyl 
derivatives with the 8-alkoxy moiety (CHŁOŃ-RZE-
PA et al., 2007), the replacement of the ethoxy or 
propoxy moiety by morpholinyl in the group of 
purine-2,6-diones resulted in a decrease in the 5-
HT1A/7 affi nity and in a slight increase in the affi ni-
ty for 5-HT2A sites. However, the obtained results 
have proven that the introduction of a methoxy 
moiety in the 2-position or a chloride atom in the 
3-position of the phenylpiperazine structure of 
8-morpholin-4-yl-purin-2,6-dione modifi ed the 
affi nity for 5-HT1A, 5-HT2A and 5-HT7 receptors as 
compared with the unsubstituted parent com-
pound (the GR-26/10 compound). The affi nity of 
the 2-methoxyphenylpiperazine derivative (com-
pound GR-27/10) signifi cantly increased for 5-
HT1A and 5-HT7 receptors, and at the same time 
it decreased about three times for 5-HT2A sites. 
However, the affi nity of the GR-28/10 compound 
with a 3-chloro substituent in the phenylpipera-
zine structure highly (4-11 times) increased for 5-
HT1A and 5-HT2A receptors. Our results have also 
confi rmed that, as compared with the previous 
report (CHŁOŃ-RZEPA et al., 2007), the introduction 
of a chloride substituent into the phenylpiperazi-
ne derivative group resulted in an almost 10-fold 
increase in 5-HT7 affi nity in the case of GR-28/10 
vs. GR-26/10 compounds. It was also found that 
the modifi cation in the arylpiperazine moiety by 
introducing the OCH3 group in the 2-position 
(GR-27/10) slightly increased (about three times) 
the affi nity for 5-HT7 receptor vs. the GR-26/10 
compound (Table1).
The in vitro binding studies have indicated 
that two of the newly synthesized derivatives of 
TABLE 1. The structure and binding affi nity of the investigated 7-arylpiperazinylbutyl-8-morpholin-4-yl-purine-2,6-dione ana-
logs for serotonin receptors.
Compound R
Ki (nM) ± SEM
5-HT1A 5-HT2A 5-HT7
GR-26/10 H 138 ± 12 77 ± 6 1277 ± 76
GR-27/10 2-OCH3 7 ± 1 205 ± 26 335 ± 15
GR-28/10 3-Cl 22 ± 2 21 ± 2 112 ± 10
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7-arylpiperazinylbutyl-8-morpholin-4-yl-puri-
ne-2,6-dione (GR-27/10 and GR-28/10) display 
interesting affi nity for the above-mentioned 5-
HT receptors. Hence, their potential anxiolytic 
and antidepressant activity was examined in two 
screening behavioral models in mice.
The results obtained previously indicated that 
the series of 7-phenylalkyl-purine-2,6-diones exer-
ted anxiolytic- and/or antidepressant-like effects 
(CHŁOŃ-RZEPA et al., 2007). The forced swim test in 
mice was carried out to investigate antidepressant-
like activity of GR-27/10 and GR-28/10 analogs 
and their effects were compared with those of the 
reference compound imipramine. The studied anti-
depressant drug signifi cantly reduced the immobi-
lity time of mice when applied at doses of 10 mg/kg 
(a 52% reduction) and 20 mg/kg (a 26.5% reduc-
tion), but not at a dose of 5 mg/kg. The investigated 
compound GR-27/10 dose-dependently decreased 
the immobility time; however, it did not reach the 
statistically signifi cant level. GR-28/10 did not pro-
duce an antidepressant-like effect; on the contrary, 
it signifi cantly (at a dose of 30 mg/kg) increased the 
immobility time of mice in Porsolt’s test (Table 2).
To investigate anxiolytic-like activity, the four-
plate test was carried out in mice. The reference 
compound diazepam at doses of 1.25, 2.5 and 5 
mg/kg dose-dependently increased (by 38%, 52% 
and 57%, respectively) the number of punished 
crossings in mice. The GR-28/10 compound ad-
ministered at a dose of 5 mg/kg signifi cantly (by 
46%) increased the number of punished crossing 
in that test. The GR-27/10 compound showed no 
anxiolytic-like effect in that test; it did not chan-
ge the number of punished crossing as compared 
with the vehicle group (Fig.1).  
The infl uence of the effective doses recorded 
only in the four-plate test was studied in the case 
of spontaneous locomotor activity in mice in order 
to exclude the possibility of competing behaviors 
such as general locomotor activity. The sponta-
neous locomotor activity was determined in sepa-
rate groups of mice. During the 1- or 5-minute 
observation period diazepam diminished sponta-
neous locomotor activity but it did not evoke the 
statistically signifi cant effect, while the investiga-
ted compound GR-28/10 produced a signifi cant 
reduction in mouse activity (Table 3). Since both 
the tested compounds do not stimulate sponta-
neous locomotor activity, their anxiolytic-like ef-
fect observed in the four-plate test in mice seems 
to be specifi c.
In conclusion, we have shown that the repla-
cement of the ethoxy or propoxy moiety with mor-
pholinyl in the group of purine-2,6-diones resulted 
in a decrease in the 5-HT1A/7 affi nity and in a slight 
TABLE 2. The effects of the compounds GR-27/10 and GR-28/10 in the forced swim test in mice
All the compounds were administrated i.p. 30 min before the test; n=8-9 mice per group.  
 a p<0.05, bp<0.001 versus the respective vehicle group
Treatment Dose (mg/kg) Immobility time (s)Mean ± SEM
Vehicle - 154.9 ± 8.3
GR-27/10
10 149.9 ± 12.0
20 139.6 ± 18.6
30 105.1 ± 18.0
F(3,28)=2.278 ns
GR-28/10
10 188.0 ± 9.3
20 178.3 ± 8.1
30 200.6 ± 11.8a
F(3,30)=4.001 p<0.05
Vehicle - 162.7 ± 6.8
Imipramine
5 170.4 ± 10.9
10 77.8 ± 12.2b
20 119.6 ± 13.0a
F(3,36)=16.7570 p<0.0001
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increase in the affi nity for 5-HT2A sites. Moreover, 
the obtained results have proven that the intro-
duction of a methoxy moiety in the 2-position or 
a chloride atom in the 3-position of the phenylpi-
perazine structure of 8-morpholin-4-yl-purin-2,6-
dione modifi ed the affi nity for 5-HT1A, 5-HT2A and 
5-HT7 receptors as compared with the unsubstitu-
ted parent compound (the GR-26/10 compound). 
Among them, the GR-28/10 compound with the 
chloride substituent in the 3-position of phenylpi-
perazine revealed activity in the screening animal 
model of anxiety in mice. However, its sedative 
effect practically excluded this ligand from being 
regarded as a potential drug.
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